Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D, Tehrani AA, Simon R, Tennstedt P, Graefen M, Wittmer C, Brors B, Plass C, Korbel J, Weischenfeldt J, Sauter G, Huland H, Tsourlakis MC, Minner S, Schlomm T. Steurer S, et al. Among authors: krohn a. Eur Urol. 2014 Dec;66(6):978-81. doi: 10.1016/j.eururo.2014.06.027. Epub 2014 Jul 9. Eur Urol. 2014. PMID: 25015038
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T. Krohn A, et al. Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13. Am J Pathol. 2012. PMID: 22705054
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S. Kluth M, et al. Among authors: krohn a. Mod Pathol. 2013 Jul;26(7):975-83. doi: 10.1038/modpathol.2012.236. Epub 2013 Feb 1. Mod Pathol. 2013. PMID: 23370768 Free article.
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T. Weischenfeldt J, et al. Among authors: krohn a. Cancer Cell. 2013 Feb 11;23(2):159-70. doi: 10.1016/j.ccr.2013.01.002. Cancer Cell. 2013. PMID: 23410972 Free article.
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R. Burkhardt L, et al. Among authors: krohn a. Cancer Res. 2013 May 1;73(9):2795-805. doi: 10.1158/0008-5472.CAN-12-1342. Epub 2013 Mar 14. Cancer Res. 2013. PMID: 23492366
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H. Krohn A, et al. J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223. J Pathol. 2013. PMID: 23794398
Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, C Tsourlakis M, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S. Krohn A, et al. Mod Pathol. 2014 Dec;27(12):1612-20. doi: 10.1038/modpathol.2014.70. Epub 2014 Apr 25. Mod Pathol. 2014. PMID: 24762546 Free article.
Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.
Kluth M, Galal R, Krohn A, Weischenfeldt J, Tsourlakis C, Paustian L, Ahrary R, Ahmed M, Scherzai S, Meyer A, Sirma H, Korbel J, Sauter G, Schlomm T, Simon R, Minner S. Kluth M, et al. Among authors: krohn a. Int J Oncol. 2015 Apr;46(4):1637-42. doi: 10.3892/ijo.2015.2855. Epub 2015 Jan 27. Int J Oncol. 2015. PMID: 25625310
Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M, Meyer D, Krohn A, Freudenthaler F, Bauer M, Salomon G, Heinzer H, Michl U, Steurer S, Simon R, Sauter G, Schlomm T, Minner S. Kluth M, et al. Among authors: krohn a. Oncotarget. 2016 Jan 26;7(4):3897-904. doi: 10.18632/oncotarget.6597. Oncotarget. 2016. PMID: 26684029 Free PMC article.
95 results